ArrowMark Colorado Holdings LLC Sells 695,983 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

ArrowMark Colorado Holdings LLC cut its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 71.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 277,420 shares of the company's stock after selling 695,983 shares during the period. ArrowMark Colorado Holdings LLC owned 0.83% of TransMedics Group worth $17,297,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of TMDX. Atlas Capital Advisors Inc. acquired a new position in shares of TransMedics Group during the 4th quarter valued at $31,000. Hager Investment Management Services LLC purchased a new position in TransMedics Group during the 4th quarter worth $33,000. Sachetta LLC purchased a new position in TransMedics Group during the fourth quarter worth about $40,000. AlphaQuest LLC bought a new position in shares of TransMedics Group in the fourth quarter valued at approximately $52,000. Finally, Arcadia Investment Management Corp MI purchased a new stake in shares of TransMedics Group during the 4th quarter valued at $72,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Trading Up 1.3 %

Shares of NASDAQ:TMDX traded up $1.17 on Tuesday, hitting $93.38. The company had a trading volume of 727,083 shares, compared to its average volume of 1,325,357. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The firm's 50-day simple moving average is $76.39 and its two-hundred day simple moving average is $75.75. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm has a market capitalization of $3.16 billion, a price-to-earnings ratio of 99.34 and a beta of 1.91.

Analyst Ratings Changes

Several analysts have issued reports on the company. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $105.00 target price (up previously from $90.00) on shares of TransMedics Group in a research note on Tuesday, April 29th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $124.20.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.